Q4 2024 EPS Estimates for Elanco Animal Health Incorporated Raised by William Blair (NYSE:ELAN)

Elanco Animal Health Incorporated (NYSE:ELAN) – William Blair upped their Q4 2024 earnings estimates for Elanco Animal Health in a research note issued to investors on Thursday, October 10th. William Blair analyst B. Vazquez now anticipates that the company will earn $0.18 per share for the quarter, up from their previous forecast of $0.17. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health’s Q1 2025 earnings at $0.32 EPS, Q3 2025 earnings at $0.14 EPS, Q1 2026 earnings at $0.36 EPS, Q2 2026 earnings at $0.32 EPS and Q3 2026 earnings at $0.18 EPS.

Other equities analysts have also recently issued reports about the stock. Barclays lifted their price target on shares of Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, September 23rd. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th. Piper Sandler cut their price objective on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st. Finally, Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.43.

Elanco Animal Health Stock Down 2.9 %

Shares of NYSE ELAN opened at $13.95 on Monday. Elanco Animal Health has a 52-week low of $8.52 and a 52-week high of $18.80. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. The stock has a market cap of $6.89 billion, a P/E ratio of -5.26, a P/E/G ratio of 1.53 and a beta of 1.40. The firm has a 50 day moving average price of $14.46 and a 200 day moving average price of $14.94.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. The firm had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The company’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.18 earnings per share.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 100,000 shares of the stock in a transaction dated Monday, August 12th. The shares were bought at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. This trade represents a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was purchased at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the purchase, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 100,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were bought at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the purchase, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. This represents a 200.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.57% of the stock is owned by insiders.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently modified their holdings of ELAN. Mirae Asset Global Investments Co. Ltd. bought a new stake in Elanco Animal Health in the 1st quarter valued at $1,226,000. Vanguard Group Inc. lifted its stake in shares of Elanco Animal Health by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock worth $737,083,000 after buying an additional 467,196 shares during the last quarter. Jupiter Asset Management Ltd. bought a new stake in shares of Elanco Animal Health during the 1st quarter worth about $4,956,000. Davidson Kempner Capital Management LP acquired a new position in Elanco Animal Health in the 2nd quarter valued at about $839,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in Elanco Animal Health by 4.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock worth $360,425,000 after purchasing an additional 852,281 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.